Intellia Therapeutics (NTLA) News Today $10.32 -0.19 (-1.81%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$10.30 -0.02 (-0.23%) As of 01/31/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Zacks Research Issues Optimistic Estimate for NTLA EarningsFebruary 1 at 1:53 AM | americanbankingnews.comZacks Research Issues Optimistic Forecast for NTLA EarningsIntellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Equities researchers at Zacks Research boosted their Q1 2025 EPS estimates for shares of Intellia Therapeutics in a note issued to investors on Tuesday, January 28th. Zacks Research analyst R. Department now forecasts that the company willJanuary 31 at 7:27 AM | marketbeat.comLewis Asset Management LLC Has $478,000 Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Lewis Asset Management LLC cut its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 38.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 40,995 sharesJanuary 30 at 9:05 AM | marketbeat.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Average Recommendation of "Moderate Buy" from BrokeragesShares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) have been given a consensus rating of "Moderate Buy" by the nineteen ratings firms that are currently covering the firm, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a hold recommendation, eleveJanuary 30 at 4:13 AM | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Stock Rating Lowered by Morgan StanleyJanuary 29 at 2:31 AM | americanbankingnews.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Intellia Therapeutics, Inc - NTLAJanuary 28, 2025 | prnewswire.comIntellia downgraded at Morgan Stanley on lowered expectations for rare disease assetJanuary 27, 2025 | msn.comMorgan Stanley Downgrades Intellia Therapeutics (NTLA)January 27, 2025 | msn.comIntellia Therapeutics (NASDAQ:NTLA) Cut to "Equal Weight" at Morgan StanleyMorgan Stanley lowered Intellia Therapeutics from an "overweight" rating to an "equal weight" rating and dropped their price objective for the stock from $56.00 to $11.00 in a research note on Monday.January 27, 2025 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Trading Up 9% - Time to Buy?Intellia Therapeutics (NASDAQ:NTLA) Trading Up 9% - Still a Buy?January 24, 2025 | marketbeat.comIntellia doses first subject in trial of NTLA-2002 for hereditary angioedemaJanuary 24, 2025 | msn.comIntellia Jumps on Test AnnouncementJanuary 23, 2025 | baystreet.caIntellia Therapeutics announces first patient dosed in Phase 3 NTLA-2002January 23, 2025 | markets.businessinsider.comIntellia Therapeutics (NASDAQ:NTLA) Trading 9% Higher - Still a Buy?Intellia Therapeutics (NASDAQ:NTLA) Shares Up 9% - Here's WhyJanuary 22, 2025 | marketbeat.comIntellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary AngioedemaJanuary 22, 2025 | globenewswire.comAvanza Fonder AB Acquires New Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)Avanza Fonder AB bought a new stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 36,065 shares of the company's stock, valued at apJanuary 20, 2025 | marketbeat.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Bought by Hennion & Walsh Asset Management Inc.Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 125.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 120,997 sharesJanuary 19, 2025 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Sets New 12-Month Low - Here's What HappenedIntellia Therapeutics (NASDAQ:NTLA) Sets New 12-Month Low - Should You Sell?January 18, 2025 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Sets New 12-Month Low - Here's WhyIntellia Therapeutics (NASDAQ:NTLA) Sets New 52-Week Low - What's Next?January 16, 2025 | marketbeat.comIntellia Therapeutics (NTLA) Receives a Buy from Bank of America SecuritiesJanuary 14, 2025 | markets.businessinsider.comIntellia Therapeutics Disappointed Investors Again On January 9 (Rating Downgrade)January 14, 2025 | seekingalpha.comIntellia Therapeutics (NASDAQ:NTLA) Price Target Cut to $12.00 by Analysts at The Goldman Sachs GroupThe Goldman Sachs Group decreased their price objective on Intellia Therapeutics from $19.00 to $12.00 and set a "neutral" rating for the company in a report on Tuesday.January 14, 2025 | marketbeat.comIntellia slashes workforce by 27% to focus on late stage CRISPR candidatesJanuary 13, 2025 | msn.comIntellia Therapeutics price target lowered to $40 from $60 at OppenheimerJanuary 13, 2025 | markets.businessinsider.comIntellia Therapeutics (NASDAQ:NTLA) Price Target Lowered to $40.00 at OppenheimerOppenheimer lowered their target price on Intellia Therapeutics from $60.00 to $40.00 and set an "outperform" rating on the stock in a report on Monday.January 13, 2025 | marketbeat.comIntellia Therapeutics’ Strategic Reorganization and Promising Clinical Progress Justify Buy RatingJanuary 13, 2025 | markets.businessinsider.comStrategic Focus and Financial Resilience: Terence Flynn’s Positive Outlook on Intellia TherapeuticsJanuary 11, 2025 | markets.businessinsider.comIntellia Therapeutics price target lowered to $60 from $70 at Wells FargoJanuary 11, 2025 | finance.yahoo.comWedbush Reiterates "Neutral" Rating for Intellia Therapeutics (NASDAQ:NTLA)Wedbush reaffirmed a "neutral" rating and set a $10.00 price target (down previously from $14.00) on shares of Intellia Therapeutics in a report on Friday.January 10, 2025 | marketbeat.comWhy Is Intellia Therapeutics Stock Trading Lower On Friday?January 10, 2025 | benzinga.comIntellia Therapeutics to Lay Off 27% of Workers in ReorganizationJanuary 10, 2025 | marketwatch.comIntellia Therapeutics stock falls following strategic reorganizationJanuary 10, 2025 | investing.comStrategic Shifts and Promising Pipelines Position Intellia Therapeutics for GrowthJanuary 10, 2025 | markets.businessinsider.comIntellia Therapeutics announces net workforce reduction of 27% in 2025January 10, 2025 | markets.businessinsider.comIntellia cuts 27% of workforce as it eyes commercial launchJanuary 10, 2025 | bizjournals.comIntellia to cut 27% of workforce, discontinue NTLA-3001January 10, 2025 | msn.comIntellia Therapeutics (NASDAQ:NTLA) Reaches New 12-Month Low After Analyst DowngradeIntellia Therapeutics (NASDAQ:NTLA) Hits New 1-Year Low After Analyst DowngradeJanuary 10, 2025 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Price Target Lowered to $50.00 at BMO Capital MarketsBMO Capital Markets dropped their price target on shares of Intellia Therapeutics from $70.00 to $50.00 and set an "outperform" rating for the company in a research report on Friday.January 10, 2025 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Price Target Cut to $60.00 by Analysts at Wells Fargo & CompanyWells Fargo & Company cut their target price on Intellia Therapeutics from $70.00 to $60.00 and set an "overweight" rating on the stock in a research note on Friday.January 10, 2025 | marketbeat.comIntellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z)January 9, 2025 | globenewswire.comEquities Analysts Issue Forecasts for NTLA FY2029 EarningsIntellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Equities research analysts at Brookline Capital Management issued their FY2029 earnings per share (EPS) estimates for shares of Intellia Therapeutics in a research note issued to investors on Monday, January 6th. Brookline Capital ManagemeJanuary 8, 2025 | marketbeat.comMichael P. Dube Sells 1,372 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) StockJanuary 8, 2025 | insidertrades.comIntellia Therapeutics price target lowered to $47 from $54 at RBC CapitalJanuary 8, 2025 | markets.businessinsider.comIntellia Therapeutics price target lowered to $50 from $58 at BofAJanuary 8, 2025 | markets.businessinsider.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) CAO Michael P. Dube Sells 1,372 SharesIntellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) CAO Michael P. Dube sold 1,372 shares of the stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total value of $16,710.96. Following the sale, the chief accounting officer now directly owns 45,640 shares in the company, valued at approximately $555,895.20. This trade represents a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.January 7, 2025 | marketbeat.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) CEO Sells $326,509.26 in StockIntellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) CEO John M. Leonard sold 26,807 shares of the business's stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total value of $326,509.26. Following the transaction, the chief executive officer now directly owns 941,115 shares in the company, valued at approximately $11,462,780.70. This represents a 2.77 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.January 7, 2025 | marketbeat.comIntellia Therapeutics reports inducement grants under Nasdaq listing ruleJanuary 7, 2025 | markets.businessinsider.com2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025 (NTLA)Gene editing is a reality and it has potential to cure hereditary diseases in a single treatment. These 2 stocks are pioneers in the CRISPR/Cas-9 space.January 7, 2025 | marketbeat.comIntellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)January 6, 2025 | globenewswire.comIntellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Recommendation of "Moderate Buy" by BrokeragesShares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the eighteen ratings firms that are covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation, elJanuary 5, 2025 | marketbeat.com Get Intellia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. Email Address NTLA Media Mentions By Week NTLA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NTLA News Sentiment▼0.110.69▲Average Medical News Sentiment NTLA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NTLA Articles This Week▼147▲NTLA Articles Average Week Get Intellia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Organon & Co. News Scholar Rock News Biohaven News Ultragenyx Pharmaceutical News Alvotech News ADMA Biologics News Viking Therapeutics News Apellis Pharmaceuticals News Avidity Biosciences News PTC Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NTLA) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredNow that Trump’s be inaugurated, this day will be key (mark your calendar)Mark your calendar for March 13th. Because on that day, I believe we could see a $2 Trillion shock INTO the...Timothy Sykes | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intellia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NTLA Stock Alerts